Introduction
Prenatal genetic diagnosis of rare disorders is undergoing in recent years a significant enhancement through the application of methods of massive parallel sequencing. In recent years Next Generation Sequencing (NGS) has become an important tool not only for gene discovery and research area but also for clinical diagnosis. To date, few studies have described the clinical use of NGS in prenatal diagnosis, most of which have concentrated on the study of single case report [1] [2] [3] [4] [5] [6] [7] . However, only a very limited number have evaluated the use of NGS for the identification of chromosome aneuploidies and rearrangements following birth [2] and before birth [3] . Despite the quantity and quality of the data produced, just few analytical tools and software have been developed in order to identify structural and numerical chromosomal anomalies through NGS, mostly not compatible with bench top NGS platform and routine clinical diagnosis. The current gold standard method for chromosomal micro deletions and micro duplications analysis is comparative genomic hybridization microarray (aCGH). The advantage of using NGS for a combined analysis of point mutations (SNPs), indels, aneuploidies, and CNVs (Copy Number Variations) is to increase the analysis resolution and detection rate with one single test. In addition this approach could allows SNPs analysis on locus affected by microdeletion/microduplication on the other allele or on correlated loci, so providing any possible information regarding genomic region and clinical effects.
We show a new targeted resequencing approach applied to prenatal diagnosis. For library preparation we use an enrichment method developed by Illumina; gene panel includes 4,813 genes, a cumulative target region size of 12 Mb, for a total of about 62,000 exons covered. Using a producer validated kit allowed us to avoid the development and validation of library for each gene of interest, obtaining 20X as minimum target coverage value. This strategy is consistent with small amount and quality of DNA extracted from prenatal sample, and especially with timing provided by prenatal diagnosis. After sequencing our bioinformatic pipelines allow both SNPs analysis for approximately thirty diseases or diseases family involved in fetus development and associated to 152 genes included in gene panel and structural and numerical chromosomal anomalies screening.
Here we show results obtained for chromosomal analysis using for NGS data processing Nextgene Software (Softgenetics). For this evaluation trial we compared NGS data to aCGH.
Materials and Methods

Choice of samples to be analysed and their processing
We analyzed 248 samples using both aCGH and NGS. The samples studied were obtained through DNA extraction from amniotic fluid and chorionic villi (QIAamp DNA Blood Mini Kit, Qiagen). Following extraction, the DNA is quantified through the Qubit® 2.0 Fluorometer system (Life technologies) and 2100 Bioanalyzer Instruments (Agilent Technologies).
aCGH: For aCGH analysis, we used BAC-array CytoChip Focus Constitutional following the manufacturer's instructions.
With BAC-array CytoChip Focus Constitutional, it is possible to perform genome analysis through 1Mb resolution and 100-200 Kb resolution for 106 selected syndromic regions.
Next generation sequencing: library preparation and analysis
The targeted resequencing was performed using an illumina kit; a trusight one sequencing panel on a NEXTSEQ500 platform. This kit makes it possible to perform enrichment and final analysis of a panel of approximately 5000 genes. A Trusight one sequencing panel contains all the reagents necessary for the amplification, amplicon enrichment, indexing of the samples and the use of NextSeq 500 without needing any external reagents. Each procedure was realized following the manufacturer's instructions.
The NEXTSEQ500 system provides fully integrated on-instrument data analysis software. Base space Reporter software performs secondary analysis on the base calls and Phred-like quality score (Qscore) generated by Real Time Analysis software (RTA) during the sequencing run. The Trusight one sequencing panel workflow in NEXTSEQ500 Reporter evaluates short regions of amplified DNA (amplicons) for variants through the alignment of reads against a "manifest file" specified while starting the sequencing run. The manifest file is provided by Illumina and contains all the information on the custom assay. The workflow requires the reference genome specified in the manifest file (Homo sapiens, hg19, build 37.2). The reference genome provides variant annotations and sets the chromosome sizes in the BAM file output. The Trusight one sequencing panel workflow performs demultiplexing of indexed reads, generates FASTQ files, aligns reads to a reference, identifies variants, and writes output files for the Alignment folder. SNPs and short indels are identified using the Genome Analysis Toolkit (GATK), by default. GATK calls raw variants for each sample, analyzes variants against known variants, and then calculates a false discovery rate for each variant. Variants are flagged as homozygous (1/1) or heterozygous (0/1) in the variant call file sample column. Because a SNP database dbSNP (http://www.ncbi.nlm.nih.gov/ projects/SNP) is available in the Annotation subfolder of the reference genome folder, any known SNPs or indels are flagged in the VCF output file. A reference gene database is available in the Annotation subfolder of the reference genome folder and any SNPs or indels that occur within known genes are annotated.
Each single variant reported in the VCF output file has been evaluated for the coverage and the Qscore and visualized via an Integrative Genome Viewer (IGV). Based on the guidelines of the American College of Medical Genetics and Genomics, all regions that have been sequenced with a sequencing depth <30 were considered unsuitable for analysis. Furthermore, we established a minimum threshold in Qscore of 30 (base call accuracy of 99.9%). For variant calling we used Variant Studio software (Illumina). For selection and reporting we used HGMD professional and ClinVar NCBI database.
Copy number variation analysis
Bam file obtained from sequencing were processed by Nextgene software (Sotgenetics) for copy number analysis.
Nextgene software (Sftgenetics) was developed for Copy-Number Variation (CNV) detection from a wide variety of projects, including whole-exome and targeted sequencing panels. Copy number variations are detected by comparing the coverage (RPKM) of specified regions in a "sample" project and a "control" project. The coverage ratio (sample divided by sample plus control) is used as the basis for CNV detection. A beta-binomial model is fit to the coverage ratio (similar to the recently published) ExomeDepth software in order to model the amount of dispersion. Likelihood values are calculated based on the dispersion measurements and coverage ratios. These probabilities are then entered into a Hidden Markov Model (HMM) to make CNV classifications for each region.
The resulting report gives a simple classification for each regioneither "Duplication" (increased copy number), "Normal" (little evidence of a CNV), "Deletion", or "Uncalled" (due to low coverage). Additionally, each region receives three phred-scaled probability scores-Deletion, Normal, and Duplication.
One "sample" project and one "control" project are loaded into the CNV menu. The regions are identified-either by annotation, incremental length, or a BED file. A BED file specifying amplicon locations is created for targeted sequencing projects, and exon locations are useful for whole-exome sequencing. For automatic fitting, the raw data is grouped to generate "fitting points" describing the dispersion at a given level of coverage.
A line is fit to these points and used to calculate the dispersion value for each region. The number of fitting points is automatically set based on the number of regions but it may be set manually instead. As a rule of thumb, there should be at least 4 to 5 fitting points and at least 100 raw data points per fitting point.
The goal of fitting the equation is to measure the amount of dispersion (noise) present in "normal" regions. The coverage ratio is expected to be equal to 0.5 for regions in the absence of a CNV. There is some randomness expected for this value, with higher-coverage regions showing a tighter distribution around the expected value than lowercoverage regions. The software first splits the data up into groups based on the total coverage, generating a summary "fitting point" for each group based on measured dispersion and the median coverage. A line is fit to these "fitting points" and the equation for this line is used to calculate dispersion for every individual region.
The dispersion value is used to calculate parameters for a beta distribution, which is used to generate a confidence interval. A higher dispersion value gives a broader CI because the ratios are expected to be more widely dispersed. If the expected CNV frequency is 10%, the software will calculate fitting points by incrementing the dispersion value until it produces an appropriate 90% (equal to 100%-10%) Confidence Interval (CI) of ratios. An appropriate confidence interval is one where the lower half of the CI is lower than the 5 th percentile ratio of the real data (because Duplication=5% and Deletion=5% in this case), or the upper half of the confidence interval is greater than the 95 th percentile. This one-sided fitting allows the software to be tolerant of CNVs that cause the raw data to have an asymmetrical distribution.
Dispersion values calculated for each region are used to generate normalized (probability of Normal+Duplication+Deletion=1) betabinomial distributions (Figure 1e ). When dispersion in a given region is high, the likelihood for any one call is low except for extreme ratio values (close to 0.0 or 1.0). The HMM used to make CNV calls makes some assumptions. The initial likelihood of each state is related to the expected CNV frequency, as is the probability of transitioning from a "normal" region to a region with a CNV. Once a region is called as a CNV, the next region is assumed to have a 50% chance of continuing that CNV or going back to normal. This transition probability enables the HMM to both ignore possibly erroneous ratios from single regions and also identify long CNVs where no individual region in the call has a very high probability. (Figure 1f ). Generally deletion calls can be more confident than duplication calls because the expected heterozygous ratio (0.333) is farther away from the normal ratio (0.5) than the heterozygous duplication ratio (0.6).
Results
We analyzed samples obtained from amniocentesis or chorionic villi sampling. Here we show results obtained through aCGH and NGS for chromosomal analysis.
Of the 248 samples analyzed using both aCGH (CytoChip Focus Constitutional BAC-array platform) and NGS data through NextGENe Software (Softgenetics), we identified nine samples affected by aneuploidies and chromosomal micro deletions/micro duplications. In Table 1 and Figures 1a-1j , we showed results obtained for positive samples and an example for negative sample.
As shown above, for nine positive samples, results were overlapping between aCGH and NGS. Remarkable for samples C6, C7 and C9 the extension of CNVs was identical for both the techniques used, whereas for samples C3, C4, C5 and C8, CNVs extension was found to be less than what was revealed using aCGH, with a difference ranging from 1 Mb (sample C5) and 3 Mb (sample C3). The size difference is probably associated to using an exome-like enrichment for NGS library preparation, carrying out for analysis only coding regions and intron regions flanking exons. Furthermore, NGS approach was able to identify chromosomal mosaicism on sample C2 (trisomy 21 present in 40% of the metaphases analyzed) and C6 (duplication of region 22q11.2 present in 45% of the metaphases analyzed).
Nextgene Software allowed to identify chromosomal location, genes involved in chromosomal aberration, length and values obtained for deletion or duplication relating to reference comparison used during sample processing (Table 2) .
For each case, we performed an analysis for missense mutation, frame shift, splicing, stop codon gained/lost, in frame insertion/in frame deletion through Variant Studio Software.
Discussion
In recent years Next Generation Sequencing (NGS) has become an important tool not only for gene discovery and research area but also for clinical diagnosis. To date, Next Generation Sequencing has been predominantly used for SNPs/Indel diagnosis and only in a few cases for detection of chromosomal aneuploidy [5] [6] [7] ; however for chromosomal screening were used whole-genomic approach, not compatible to prenatal diagnosis for timing and sample type. Here we showed NGS application in prenatal diagnosis both for SNPs analysis and chromosomal screening.
We used a Next Generation Sequencing method based on the use of an enrichment gene panel library produced by Illumina and including 4,813 genes. After sequencing our bioinformatic pipelines allows SNPs and structural/numerical chromosomal anomalies analysis. For SNPs analysis we selected a genes pool (about 152 genes) associated approximately to thirty diseases or diseases family involved in fetus development, targeted exome-like approach. Using a producer validated We used dedicated software (Nextgene, Sofgenetetics) to carry out copy number variation analysis of data obtained from NGS. This evaluation was performed through comparison to aCGH, the gold standard technique for the identification of chromosome aneuploidies, microdeletions and microduplications.
The results are comparable with those obtained from aCGH both for chromosomal aneuploidy that for CNVs extension between 10 Mb and less than 1 Mb. This system has a number of advantages compared to the use of microarray. Using a single analytical tool for Mendelian disorders and chromosomal abnormalities screening, makes NGS compatible to prenatal diagnosis. Moreover, with similar resolution level to aCGH, it is possible to obtain clear clinical effects of chromosome anomalies, considering not only chromosome position and size of microdeletion/ microduplication but also sequencing analysis of same locus on the other allele. This makes it possible to exclude possible pathogenetic SNPs that cannot be identified through aCGH.
In the future, we will use an enrichment panel similar to the one used in this study, but it will include 19,000 genes and we will compare the results obtained with a higher resolution array CGH platform.
